HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

IFRA defends QRA

This article was originally published in The Rose Sheet

Executive Summary

Despite advocacy group Cropwatch's call to boycott the International Fragrance Association's 40th amendment to its Code of Practice, which implements a quantitative - versus qualitative - risk assessment method for gauging fragrance allergenicity, the initiative is moving ahead as planned, IFRA members said Feb. 28 during CTFA's annual meeting in Boca Raton, Fla. "Cropwatch was saying basically that the QRA system was too complicated for smaller companies - too expensive and cumbersome," IFRA Director General Jean-Pierre Houri noted. "But we cannot put our head in the sand and refuse what is considered to be by the best scientific minds as a major step forward in the field of dermal sensitization." IFRA maintains that the new system allows perfumers more flexibility in designing fragrances and that it allows the association to "lead, rather than follow," according to Anne Marie Api, Ph.D, VP of Human Health Sciences for RIFM. "We [will] be frontrunners. We [will] be leading and showing that we're taking responsibility for the fragrance allergy issue." Cropwatch announced its boycott in January (1"The Rose Sheet" Jan. 29, 2007, p. 3)...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS014570

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel